Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Zendy

Manesh R. Patel | Zendy; Kenneth W. Mahaffey | Zendy; Jyotsna Garg | Zendy; Guohua Pan | Zendy; Daniel E. Singer | Zendy; Werner Hacke | Zendy; Günter Breithardt | Zendy; Jonathan L. Halperin | Zendy; Graeme J. Hankey | Zendy; Jonathan P. Piccini | Zendy; Richard C. Becker | Zendy; Christopher C. Nessel | Zendy; John F. Paolini | Zendy; Scott D. Berkowitz | Zendy; Keith A.A. Fox | Zendy; Robert M. Califf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Author(s) -

Manesh R. Patel,

Kenneth W. Mahaffey,

Jyotsna Garg,

Guohua Pan,

Daniel E. Singer,

Werner Hacke,

Günter Breithardt,

Jonathan L. Halperin,

Graeme J. Hankey,

Jonathan P. Piccini,

Richard C. Becker,

Christopher C. Nessel,

John F. Paolini,

Scott D. Berkowitz,

Keith A.A. Fox,

Robert M. Califf

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1009638

Subject(s) - rivaroxaban , medicine , warfarin , atrial fibrillation , hazard ratio , stroke (engine) , clinical endpoint , confidence interval , embolism , anesthesia , cardiology , randomized controlled trial , surgery , mechanical engineering , engineering

The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research